Prediction of Effectiveness of rTMS Application in Alzheimer's Patients
ConditionAlzheimer Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55+
SponsorIstanbul Medipol University Hospital
About this trial
Since pharmacological methods are insufficient in the treatment processes of Alzheimer's disease, non-pharmacological methods such as Transcranial Magnetic Stimulation (TMS) have started to be tried as a treatment option as in other neurological and psychiatric diseases. Repeated (rTMS) offers a potential treatment pathway for neurological and psychiatric illnesses. rTMS benefit rate may vary depending on many factors such as the region where it is applied, the progression and the disease degree. The possible effects of TMS on Alzheimer's pathophysiology and modification of disease process (neuroprotective, anti-inflammatory and antioxidant) will also be revealed through blood samples taken from patients before and after treatment. These approaches also constitute the original value of our study.
Eligibility criteria
Qualifiers
Have been diagnosed with clinical Alzheimer's Disease in accordance with the NINCDS-ADRDA diagnostic criteria
>55 years old
Clinical Dementia Rating Scale (CDR) score in the 1-2 range
Not having any other disease that affects their cognitive functions
Disqualifiers
Participant or relative does not give consent
The patient's inability to participate in the entire study procedure (eg living in another city)
The patient's history of head trauma with alcohol/substance abuse
Presence of severe stroke and other neurological sequelae disease in the participant
Trial design
Treatments tested in this trial
- Repetetive Transcranial Magnetic Stimulation
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Istanbul Medipol University Hospital
Lead sponsor
Bezmialem Vakif University
Collaborator
Saglik Bilimleri Universitesi
Collaborator
Source ClinicalTrials.gov